Back to Search Start Over

The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM).

The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM).

Authors :
Canavan ME
Westvold S
Csik V
Franks J
Rocque G
Gross CP
Adelson KB
Source :
Journal of the National Cancer Institute [J Natl Cancer Inst] 2025 Jan 22. Date of Electronic Publication: 2025 Jan 22.
Publication Year :
2025
Publisher :
Ahead of Print

Abstract

It has long been assumed that academic oncology practices are disadvantaged in value-based payment programs, due to patient complexity and research costs. This assumption not been tested. The Oncology Care Model (OCM) was a Medicare alternative payment model, which sought to curb costs while improving care. We assessed the impact of clinical trial (CT) participation on two outcomes: 1. cost and 2. practice performance among three participating NCI designated cancer centers using a random effects meta-analysis. The mean total Medicare cost per episode was $42,225 for CT episodes and $34,937 for non-CT episodes. Despite higher total costs, CT episodes were more likely to be under spending targets than non-CT episodes (odds ratio 0.37 (CI 0.25, 0.48). Drug costs in CT episodes were lower than in non-CT episodes, although this was only statistically significant at the largest volume practice. In conclusion, CTs may offer an advantage in value-based programs.<br /> (© The Author(s) 2025. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1460-2105
Database :
MEDLINE
Journal :
Journal of the National Cancer Institute
Publication Type :
Academic Journal
Accession number :
39842859
Full Text :
https://doi.org/10.1093/jnci/djaf008